Loading…
Nuclear morphometric changes and therapy monitoring in patients with endometrial hyperplasia: a study comparing effects of intrauterine levonorgestrel and systemic medroxyprogesterone
To show that local application of the levonorgestrel intrauterine device was a better therapy for endometrial hyperplasia (EH) compared to per-oral gestagen treatment based on subjective (WHO criteria) and objective (prognostic data-based morphometric and stereological method/ D score, predicting th...
Saved in:
Published in: | Gynecologic oncology 2003-12, Vol.91 (3), p.526-533 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | To show that local application of the levonorgestrel intrauterine device was a better therapy for endometrial hyperplasia (EH) compared to per-oral gestagen treatment based on subjective (WHO criteria) and objective (prognostic data-based morphometric and stereological method/
D score, predicting the risk of cancer development for each single patient) evaluation.
Women between 30 and 70 years with EH and
D score > 0 were treated with levonorgestrel intrauterine device (
n = 26) and the results compared to a historic group of women treated with per-oral gestagen (
n = 31). In both treatment groups only patients with low risk (
D score > 1) and uncertain risk (
D score = 0–1) of cancer development were included. Endometrial specimens were investigated prior to treatment and after 3 months of therapy. The endometrial samples from the two groups were examined by light microscopy and objective data-based morphometry to assess tissue characteristics and to evaluate nuclear size variation.
After 3 months all patients treated with levonorgestrel intrauterine device showed regression of hyperplasia, whereas 14 of 31 patients in the per-oral group still had persisting disease. The objective morphometric analysis showed reduction in nuclear size for both treatment groups, including the
D score > 1 as well as the
D score 0–1 patients. However, the reduction was most obvious for the levonorgestrel intrauterine device-treated patients with initial
D score of 0–1.
The present study indicates that levonorgestrel intrauterine device is a superior alternative to per oral treatment of endometrial hyperplasia. By using objective morphometric treatment monitoring we have shown that the hyperplasia patients with the highest malignant potential (
D score = 0–1) were those taking most benefit from local high-dose levonorgestrel therapy. |
---|---|
ISSN: | 0090-8258 1095-6859 |
DOI: | 10.1016/j.ygyno.2003.07.002 |